Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy

Trial Profile

A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Iadademstat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms ALICE
  • Sponsors Oryzon
  • Most Recent Events

    • 15 Sep 2018 Status changed from planning to recruiting.
    • 10 Sep 2018 According to an Oryzon media release, the company has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct this trial. The trial will be carried out in two Spanish hospitals, "La Fe" in Valencia and "Valle de Hebron" in Barcelona.
    • 30 Jul 2018 According to an Oryzon media release, the company has filed the corresponding CTA authorizations to Regulatory Agencies to carry out this trial, and will inform about its regulatory approval and the operational start thereof in due time.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top